AbCellera's platform credibility hinges on ABCL635 Phase 2 VMS data, with ABCL575 atopic dermatitis Phase 1 results close behind

Bull

A positive outcome would show statistically significant and clinically meaningful reduction in moderate-to-severe hot flash frequency and severity versus placebo, with a clean safety profile consistent with the Phase 1 tolerability data (no serious adverse events, no liver toxicity). This would validate AbCellera's end-to-end platform — from antibody discovery through clinical development — de-risking the pipeline broadly and supporting the case that ABCL575 and subsequent wholly-owned programs can reach efficacy inflection points.

Bear

The most likely failure mode is a miss on the primary efficacy endpoint — insufficient reduction in vasomotor symptom frequency or severity relative to placebo — which would call into question whether targeting testosterone suppression via this mechanism translates to meaningful symptom relief in postmenopausal women. Secondary failure modes include unexpected safety signals that undermine the tolerability profile established in Phase 1, or a treatment effect too modest to differentiate from existing hormonal and non-hormonal options, leaving the program without a viable development path.